(Reuters) - Gevo Inc started production at a converted ethanol plant in Minnesota, bringing on line the world's first commercial-scale facility to make advanced biofuels and renewable chemicals. Shares rose more than 9 percent.
(Reuters) - An arbitrator ruled Kuwait's state-run chemical company must pay Dow Chemical Co $2.16 billion for wrongly canceling a planned plastics joint venture in 2008, Dow said on Thursday.
WASHINGTON (Reuters) - America's reliance on fuel imports has sucked vigor from its economy for decades. Now an oil and natural gas boom holds out the prospect for a new era of stronger U.S. economic growth.
LOS ANGELES (Reuters) - Pharmaceutical companies, which were spared some of the more sweeping regulations in President Barack Obama's healthcare overhaul, could come under more pressure if the U.S. Supreme Court strikes down part or all of the 2010 law.
(Reuters) - Kuwait's state-run chemical company must pay Dow Chemical Co $2.16 billion under an arbitrator's ruling for wrongly cancelling a planned plastics joint venture in 2008, Dow said on Thursday.
(Reuters) - Kuwait's state-run chemical company must pay Dow Chemical Co $2.16 billion under an arbitrator's ruling for wrongly cancelling a planned plastics joint venture in 2008, Dow said on Thursday.
SILVER SPRING, Maryland (Reuters) - U.S. advisers recommended against expanding the use of Johnson & Johnson's blood thinner Xarelto as a way to reduce the risk of new heart attacks and strokes in people with heart problems.
SILVER SPRING, Maryland (Reuters) - U.S. advisers recommended against expanding the use of Johnson & Johnson's blood thinner Xarelto as a way to reduce the risk of new heart attacks and strokes in people with heart problems.
SILVER SPRING, Maryland (Reuters) - U.S. advisers recommended against expanding the use of Johnson & Johnson's blood thinner Xarelto as a way to reduce the risk of new heart attacks and strokes in people with heart problems.
SILVER SPRING, Maryland (Reuters) - A U.S. advisory panel rebuffed Johnson & Johnson's blood thinner, meant to reduce the risk of new heart attacks and strokes in people with heart problems.
PARIS (Reuters) - The meteoric rise of a natural, healthy alternative to sugar - a holy grail for the food industry - might just be a little too good to be true.
PARIS (Reuters) - The meteoric rise of a natural, healthy alternative to sugar - a holy grail for the food industry - might just be a little too good to be true.